Liver study tests how drug AZD2693 behaves in impaired patients
NCT ID NCT05919069
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how a single dose of the drug AZD2693 moves through the body in people with liver impairment compared to healthy volunteers. Researchers measured drug levels in the blood to understand safety and processing differences. A total of 35 adults took part. The goal was to gather information for future dosing recommendations, not to treat the liver condition itself.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Rialto, California, 92377, United States
-
Research Site
Miami Lakes, Florida, 33014, United States
-
Research Site
Orlando, Florida, 32808, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Liver health and drug processing: a closer look at casdatifan
- Liver function may change how belapectin works in the body
- Liver function may change how ammoxetine works
- Liver function may affect how Weight-Loss drug petrelintide works
- Liver health may change how a promising cancer drug works in the body
- Liver health may change how body handles inhaled lung drug